Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

HPN328, a Trispecific T Cell-Activating Protein Construct Targeting DLL3-Expressing Solid Tumors.

Molecular cancer therapeutics·2024

Same author

Brentuximab Vedotin-Driven Microtubule Disruption Results in Endoplasmic Reticulum Stress Leading to Immunogenic Cell Death and Antitumor Immunity.

Molecular cancer therapeutics·2023

Same author

Studying the Presentation of Paget Disease of the Breast.

Cureus·2023

Same author

Studying the Co-presentation of Focal Segmental Glomerulosclerosis and IgA Nephropathy in a Young Female With No Significant Risk Factors.

Cureus·2023

Same author

Conduit CAR: Redirecting CAR T-Cell Specificity with A Universal and Adaptable Bispecific Antibody Platform.

Cancer research communications·2023

Same author

Soluble RAGE Prevents Type 1 Diabetes Expanding Functional Regulatory T Cells.

Diabetes·2022

Search research articles

Related Experiment Video

Updated: Jun 20, 2026

Generation of Human CD40-activated B cells

Generation of Human CD40-activated B cells

Published on: October 16, 2009

Targeting CD70 for human therapeutic use.

Tamar E Boursalian¹, Julie A McEarchern, Che-Leung Law

¹Department of Preclinical Therapeutics, Seattle Genetics, Inc., Bothell, Washington, USA.

Advances in Experimental Medicine and Biology

|September 18, 2009

Summary

This summary is machine-generated.

CD70, a molecule on immune cells, plays a key role in T-cell and B-cell responses. Targeting the CD70-CD27 interaction shows promise for treating autoimmune diseases and cancers.

More Related Videos

Murine Model of CD40-activation of B cells

Murine Model of CD40-activation of B cells

Published on: March 5, 2010

Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood

Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood

Published on: February 1, 2013

Related Experiment Videos

Last Updated: Jun 20, 2026

Generation of Human CD40-activated B cells

Generation of Human CD40-activated B cells

Published on: October 16, 2009

Murine Model of CD40-activation of B cells

Murine Model of CD40-activation of B cells

Published on: March 5, 2010

Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood

Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood

Published on: February 1, 2013

Area of Science:

Immunology
Molecular Biology
Oncology

Background:

CD70, a tumor necrosis factor superfamily member, is expressed on activated lymphocytes and dendritic cells.
CD70-CD27 interaction is crucial for T-cell and B-cell immune responses, including differentiation and memory formation.
CD70 is found on various hematological tumors and carcinomas, alongside its role in autoimmune conditions.

Purpose of the Study:

To provide an overview of the physiological role of CD70-CD27 interactions.
To discuss therapeutic strategies targeting the CD70 pathway in cancer and autoimmune diseases.

Main Methods:

Review of existing literature on CD70-CD27 interactions.
Analysis of studies investigating antibody blockade of CD70-CD27.
Examination of CD70 expression patterns in normal tissues and malignancies.

Main Results:

CD70-CD27 interaction is vital for immune cell function and generation of adaptive immunity.
Antibody blockade of CD70-CD27 has shown efficacy in preclinical models of autoimmune encephalomyelitis and allograft rejection.
CD70's restricted normal tissue expression and aberrant expression in cancers make it a viable therapeutic target.

Conclusions:

The CD70-CD27 pathway represents a significant target for antibody-based therapeutics.
Targeting CD70 offers potential for treating both autoimmune disorders and various malignancies.
Further research into therapeutic approaches modulating CD70-CD27 interactions is warranted.